SCHEMBL20548002

SCHEMBL20548002

O=C1c2ccccc2C(=O)N1CCOCCOCCOCCOC1CCCCO1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4C Q9H3R0 1/20 0.42
HTR1A P08908 1/20 0.42
HTR7 P34969 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
HTR2B P41595 1/20 0.42
LMNA P02545 1/20 0.42
ACHE P22303 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 5/20 0.39
NPC1 O15118 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20547967 1.00 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19KDM4CHTR1A
SCHEMBL28910814 1.00 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19KDM4CHTR1A
SCHEMBL29929381 1.00 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19KDM4CHTR1A
SCHEMBL21069711 0.91 HPGD (0.46) CYP1A2CYP2C9CYP2C19KDM4CHTR1A
SCHEMBL23308127 0.85 MEN1 (0.37) CYP1A2CYP2C9CYP2C19KDM4CLMNA
SCHEMBL31419834 0.84 CYP1A2 (0.53) CYP1A2CYP2C9CYP2C19HTR1AHTR7
SCHEMBL21902678 0.83 ACHE (0.43) KDM4CHTR1AHTR7DRD3ACHE
SCHEMBL23308124 0.81 L3MBTL1 (0.50) CYP2C9CYP2C19KDM4CLMNAMEN1
SCHEMBL8305605 0.81 GAA (0.51) CYP1A2CYP2C9CYP2C19KDM4CMEN1
SCHEMBL6473079 0.79 CYP1A2 (0.45) CYP1A2CYP2C9CYP2C19KDM4CHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12357631-B2 Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2025-07-15 US disclosed
EP-3829719-B1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA INC (US) 2025-04-02 EP disclosed
EP-3829719-A1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION Cocrystal Pharma, Inc. (US) 2021-06-09 EP disclosed
US-11014941-B2 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2021-05-25 US disclosed
US-11014941-B2 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2021-05-25 US disclosed
US-20210121462-A1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. 2021-04-29 US disclosed
US-20210121462-A1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. 2021-04-29 US disclosed
US-20200123177-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. 2020-04-23 US disclosed
US-20200123177-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. 2020-04-23 US disclosed
EP-3615545-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION Cocrystal Pharma, Inc. (US) 2020-03-04 EP disclosed
WO-2020023813-A1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. (US) 2020-01-30 WO disclosed
WO-2020023813-A1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. (US) 2020-01-30 WO disclosed
WO-2018200425-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. (US) 2018-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014941-B2 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication ITPA, POLR2H, POLR2E CYP1A2 2397/4885CYP2C9 1114/4885CYP2C19 243/4885
US-20210121462-A1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION PIR, PNPO, IDO1 CYP1A2 808/4885CYP2C9 1259/4885CYP2C19 524/4885
US-20200123177-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION ITPA, POLR2H, POLR2E CYP1A2 2397/4885CYP2C9 1114/4885CYP2C19 243/4885
US-12357631-B2 Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication PIR, PNPO, IDO1 CYP1A2 808/4885CYP2C9 1259/4885CYP2C19 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.